Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,080 JPY | -1.21% |
|
-.--% | +2.13% |
06-24 | Hutchmed China notes Takeda obtains EU approval for Fruzaqla | AN |
06-24 | Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analyst opinion has improved significantly over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 46.05 and 70.65 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.13% | 40.23B | - | ||
+52.70% | 801B | C+ | ||
+41.58% | 631B | B | ||
-4.86% | 359B | C+ | ||
+21.96% | 337B | B- | ||
+11.47% | 305B | C+ | ||
+17.72% | 245B | B+ | ||
+4.46% | 231B | A+ | ||
+13.13% | 219B | B- | ||
+10.46% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock
- Ratings Takeda Pharmaceutical Company Limited